Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Current Assets (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Current Assets data on record, last reported at $362.2 million in Q4 2025.

  • For Q4 2025, Current Assets rose 26.67% year-over-year to $362.2 million; the TTM value through Dec 2025 reached $362.2 million, up 26.67%, while the annual FY2025 figure was $362.2 million, 26.67% up from the prior year.
  • Current Assets reached $362.2 million in Q4 2025 per ORGO's latest filing, up from $299.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $362.2 million in Q4 2025 and bottomed at $185.2 million in Q1 2021.
  • Average Current Assets over 5 years is $239.4 million, with a median of $227.1 million recorded in 2021.
  • Peak YoY movement for Current Assets: skyrocketed 71.41% in 2021, then decreased 6.52% in 2023.
  • A 5-year view of Current Assets shows it stood at $227.0 million in 2021, then fell by 1.93% to $222.6 million in 2022, then rose by 1.09% to $225.0 million in 2023, then increased by 27.06% to $285.9 million in 2024, then grew by 26.67% to $362.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $362.2 million in Q4 2025, $299.7 million in Q3 2025, and $260.2 million in Q2 2025.